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Abstract
Background: A continuous subcutaneous infusion (CSCI) delivered via syringe pump is a method of drug administration
used to maintain symptom control when a patient is no longer able to tolerate oral medication. Several classes of drugs,
such as opioids, antiemetics, anticholinergics, antipsychotics and benzodiazepines are routinely administered by CSCI
alone or in combinations. Previous studies attempting to identify the most-common CSCI combinations are now several
years old and no longer reflect current clinical practice. The aim of this work was to review current clinical practice and
identify CSCI drug combinations requiring analysis for chemical compatibility and stability.
Methods: UK pharmacy professionals involved in the delivery of care to palliative patients in hospitals and hospices
were invited to enter CSCI combinations comprised of two or more drugs onto an electronic database over
a 12-month period. In addition, a separate Delphi study with a panel of 15 expert healthcare professionals
was completed to identify a maximum of five combinations of drugs used to treat more complex, but less
commonly encountered symptoms unlikely to be identified by the national survey.
Results: A total of 57 individuals representing 33 separate palliative care services entered 1,945 drug combinations
suitable for analysis, with 278 discrete combinations identified. The top 40 drug combinations represented nearly
two-thirds of combinations recorded. A total of 23 different drugs were administered in combination and the median
number of drugs in a combination was three. The Delphi study identified five combinations for the relief of complex
or refractory symptoms.
Conclusion: This study represents the first step towards developing authoritative national guidance on the
administration of drugs by CSCI. Further work will ensure healthcare practitioners have the knowledge and
confidence that a prescribed combination will be both safe and efficacious.
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Background
A continuous subcutaneous infusion (CSCI) is a method
of drug administration used to maintain symptom con-
trol when a patient is no longer able to tolerate oral
medication. A syringe pump (also referred to as a syr-
inge driver) is used to deliver a CSCI, which is consid-
ered fundamental for continued symptom management
in palliative care [1]. Several classes of drugs, such as
opioids, antiemetics, anticholinergics, antipsychotics and
benzodiazepines are routinely administered by CSCI
alone or in combinations [2].
There have been several national surveys that have
attempted to identify commonly used mixtures [3–6].
These studies, however, are several years old and do not
reflect current practice. The most recent survey of CSCI
use in the UK was performed over a decade ago in 2004
[6]. The majority of combinations contained either two
or three drugs (44 and 30% respectively) and an opioid
was invariably a component. The authors concluded that
compatibility and stability data were unavailable for
more than half of the frequently used combinations.
This is unsurprising for two reasons. Firstly, laboratory
analysis is expensive and laborious. Secondly, the num-
ber of potential combinations is vast; Dickman et al. [2]
identified 35 drugs that could be administered by CSCI,
11 of which were opioids. Based on these figures, there
are theoretically 142,450 combinations (Fig. 1). Of
course, certain combinations of drugs are impractical, so
the number of clinically useful combinations is signifi-
cantly lower. For example, for five non-opioids and one
opioid, there are potentially 56 combinations comprising
up to five drugs.
Parenteral administration of drugs is a recognised
cause of medication error, and compatibility and stability
of drug combinations is an issue of patient safety [7].
Despite widespread application in palliative care, there
remain only three major sources of compatibility and
stability information relating to CSCIs [2, 8, 9]. These
reference sources provide information mainly about the
visual compatibility of drug combinations, often relying
on a clinical assessment to determine whether or not a
particular combination is suitable for administration by
CSCI. While many mixtures may appear physically com-
patible (i.e. clear, colourless and free from precipitation)
the risk of chemical incompatibility cannot be ignored.
There is a clear need to identify compatibility and stabil-
ity of drug combinations administered by CSCI, espe-
cially those combinations most commonly prescribed.
The aim of this project was to review current clinical
practice to identify drug combinations that require ana-
lysis for chemical compatibility and stability.
Methods
In order to identify a list of drug combinations that
would be subject to subsequent chemical analysis, two
methods were employed: a national survey of practice
and a Delphi study. This work was registered with the
Liverpool Clinical Trials Unit (LCTU), which provided
structured data monitoring, assessment and logistical
support. Members of the Association of Supportive and
Palliative Care Pharmacy (formerly Palliative Care Phar-
macists’ Network) were approached for both methods.
National survey
The national survey invited UK pharmacists and phar-
macy technicians involved in the delivery of care to
palliative patients in hospital and hospices to take part.
Over a 12-month period, participants were asked to con-
tribute to an anonymous web-based database that
recorded information pertaining to CSCIs comprising
Fig. 1 Calculation of number of possible drug combinations. Adapted from reference [35]
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two or more drugs used for symptom management of
patients aged 18 years and above during the last months
or days of life. Participants entered information into the
database about drug(s), dose(s), diluent used, total
volume of infusion, duration of infusion and visual com-
patibility. The web-based system, designed and adminis-
tered by LCTU, ensured patient anonymity while
preventing duplication of entry. The database was ana-
lysed and a list describing the most frequent 40 combi-
nations was produced. A literature search was then
performed to determine if any the top 40 combinations
identified by this national survey had already undergone
chemical analysis.
Delphi study
In addition to the national survey, a Delphi study was
undertaken using an online web questionnaire, hosted
by www.smartsurvey.co.uk. The purpose of the Delphi
study was to identify a maximum of five combinations
of drugs used to treat more complex symptoms that
required investigation for compatibility to improve the
quality of patient care. This approach was deemed
necessary as combinations prescribed for more difficult,
but less commonly encountered symptoms, would not
be identified by the national survey. The panel of experts
in this study comprised 15 healthcare professionals split
evenly between doctors, nurses and pharmacists. Each
expert was required to have at least 5 years’ palliative
care clinical experience and be involved in the prescrib-
ing of, setting up of, or checking of CSCIs.
Pharmacists were contacted and asked if there was an
interest to participate in this study, provided they met
the criteria above. They were also requested to nominate
senior medical and nursing staff at their place of work
who met the criteria and were willing to participate.
Experts were selected based on promptness of response
to agree to participate. One week before disseminating
each questionnaire, all the experts received a pre-
notification personalised email sent by the researcher.
All further communication between researcher and
respondents was indirect as the host website served as a
conduit, ensuring respondent anonymity. All partici-
pants gave informed consent before attempting each
questionnaire. The website hosting the survey anon-
ymised the questionnaires, preventing identification of
respondents by the researcher.
In the first-round of the Delphi study, the experts were
asked to identify up to 10 combinations of drugs that
had been used, or would have been used if there were
compatibility data, for the management of complex or
refractory symptoms. The experts were allowed
complete freedom with their responses. A second litera-
ture search was undertaken to determine if any of the
most common 25 combinations identified in the first-
round of the Delphi study had already undergone chem-
ical analysis. In the second round, the experts were re-
quired to select and rank ten combinations from the list
of the 25 most common combinations of drugs identi-
fied in the first-round. In the final round, the experts
were presented with the top 15 combinations derived
from the second round and asked to rank them. Due to
the potential for variability of responses, consensus
agreement was based on the mean rank order. The top
five drug combinations after three rounds were selected.
Results
A total of 57 individuals representing 33 separate pallia-
tive care services completed the national survey. At the
time the database was locked, 1,945 combinations had
been recorded (2,132 samples were collected, but 186
were excluded due to erroneous entry), with 278 discrete
combinations of drugs being identified. Analysis of the
database revealed 23 different drugs had been adminis-
tered in combination by CSCI, six of which were opioids
(see Table 1). The four most frequently prescribed drugs
(midazolam, morphine, oxycodone and levomeproma-
zine) accounted for 52% of all administered drugs. The
median number of drugs administered by CSCI was
three, with 50.6% of combinations comprising three or
more drugs. Almost all CSCIs were administered over a
duration of 24 h (1915/1945; 98.5%) with Water for
Injections (WFI) being the most commonly used diluent
(1346/1945; 69.2%). An opioid was present in 91.5% of
the combinations.
The top 40 represented nearly two-thirds of the 1,945
combinations recorded (see Table 2), comprising 20 two-
drug, 19 three-drug and 1 four-drug combinations.
Compatibility and stability data at clinically relevant
doses were available for less than one third of the top 40
combinations [10–21].
The e-Delphi study was successfully completed by all
15 healthcare professionals, enabling the identification of
five combinations used for complex or refractory symp-
toms that required analysis for compatibility and stability
(see Table 3). No compatibility and stability data were
found for these combinations. Only one of the five com-
binations appeared in the survey database (oxycodone,
glycopyrronium and levomepromazine) and all com-
prised three drugs.
Discussion
This survey represents the most recent analysis of drug
combinations administered by CSCI in the UK. The
most commonly prescribed drug administered by CSCI
was midazolam, while the most commonly prescribed
opioid was morphine. Diamorphine was identified as the
least commonly prescribed opioid. The previous national
survey, however, identified diamorphine as the opioid
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most commonly administered by CSCI [6]. The world-
wide shortage of diamorphine during the winter of 2004
forced services to adopt morphine as the opioid of
choice and it would appear that many have not reverted
to diamorphine. In 2012, the National Institute for
Health and Clinical Excellence recommended that the
parenteral opioid with the lowest acquisition cost (i.e.
morphine) should be used first-line [22]. Diamorphine,
with its superior solubility, appears to be generally
reserved for patients with a relatively high opioid
requirement, as reflected by mean and median doses of
77 mg and 30 mg respectively (Table 1).
A previous literature review found that only 70 drug
combinations suitable for administration by CSCI had
been investigated for compatibility and stability. The
majority of these (88.6%) referred to two-drug combina-
tions [23]. Indeed, a review of the literature for the top
40 combinations identified by the national survey
revealed that only 13 (32.5%) have been analysed at clin-
ically relevant doses for compatibility and stability, the
majority of which comprised two drugs. The five combi-
nations identified by the Delphi study were those mainly
associated with the management of difficult or recalci-
trant symptoms. Such combinations were expected to
occur infrequently, a supposition vindicated by the
appearance of only one combination in the database
derived from the survey. These combinations often re-
flect specialist practice. It was unclear from the survey
which area of practice the data were collected. A survey
of specialist palliative care inpatient services only would
be expected to identify a different list of commonly used
combinations. Indeed, analysis of practice at a specialist
palliative care inpatient unit revealed that 70% of the
combinations comprised three or more drugs (compared
to 50.6% in this survey) [24]. Since the majority of cur-
rently available compatibility and stability data refer to
two-drug combinations, there is a disparity between
available evidence and clinical practice.
A limitation of the Delphi technique is the risk of se-
lection bias often associated with the choice of expert
panel. Indeed, there are no universally accepted criteria
for the selection of experts using the Delphi technique
[25]. Selecting panel members through methods other
than acquaintance is believed to minimise bias [26, 27].
In an attempt to reduce the risk of researcher bias, ex-
perts were selected for the Delphi study through a mix
of promptness of response to the call to participate and
snowballing. Both methods, however, may be associated
Table 1 Frequency and doses of drugs that appeared in the database
Drug Frequency 1st quartile dose (mg) 3rd quartile dose (mg) Mean dose (mg) Median dose (mg)
Midazolam 1002 10 20 16.6 10.0
Morphine 568 10 40 32.0 20.0
Oxycodone 549 15 60 52.5 30 .0
Levomepromazine 514 6.25 25 22.0 12.5
Haloperidol 492 2.5 3 3.0 3.0
Alfentanil 359 2 14 37.8 5.0
Hyoscine butylbromide 330 60 120 86.9 80.0
Diamorphine 289 10 80 77.7 30.0
Metoclopramide 276 30 60 49.8 40.0
Cyclizine 171 150 150 143.4 150.0
Clonazepam 165 0.5 2 1.72 1.0
Glycopyrronium 116 0.6 1.2 1.13 1.2
Dexamethasone 93 0.5 16 1.73 8.0
Octreotide 56 0.3 1 0.5 0.6
Ketamine 30 60 350 220.2 175.0
Ondansetron 21 8 20 14.5 12.0
Granisetron 12 2 4 3.25 3.5
Methadone 12 35 60 44.8 52.5
Hyoscine hydrobromide 8 0.6 1.6 1.3 1.4
Ketorolac 5 60 60 60.0 60.0
Hydromorphone 4 70 90 80.0 80.0
Ranitidine 4 150 225 162.8 150.0
Diclofenac 1 75 75 75.0 75.0
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Table 2 Top 40 combinations present in the 1,945 recorded CSCIs
Drug Combination Frequency
Drug 1 Drug 2 Drug 3 Drug 4
Morphine Midazolam - - 124a
Oxycodone Midazolam - - 81a
Oxycodone Levomepromazine Midazolam - 60
Morphine Metoclopramide - - 57
Diamorphine Midazolam - - 55a
Morphine Levomepromazine Midazolam - 53
Oxycodone Haloperidol Midazolam - 52
Oxycodone Haloperidol - - 49a
Morphine Haloperidol Midazolam - 46
Alfentanil Haloperidol - - 36
Oxycodone Levomepromazine - - 35a
Alfentanil Midazolam - - 35
Alfentanil Levomepromazine Midazolam - 34
Morphine Haloperidol - - 29
Oxycodone Metoclopramide - - 29a
Oxycodone Haloperidol Hyoscine butylbromide - 29a
Morphine Cyclizine - - 28
Morphine Levomepromazine - - 22a
Alfentanil Haloperidol Midazolam - 22a
Diamorphine Metoclopramide - - 21a
Alfentanil Metoclopramide - - 21
Alfentanil Hyoscine butylbromide Levomepromazine - 20
Oxycodone Metoclopramide Midazolam - 20
Diamorphine Cyclizine - - 19a
Diamorphine Haloperidol Midazolam - 19
Oxycodone Hyoscine butylbromide Midazolam - 18
Alfentanil Hyoscine butylbromide Levomepromazine Midazolam 18
Alfentanil Metoclopramide Midazolam - 17
Morphine Hyoscine butylbromide Midazolam - 17
Diamorphine Levomepromazine - - 17a
Diamorphine Levomepromazine Midazolam - 17
Morphine Haloperidol Hyoscine butylbromide - 17
Morphine Metoclopramide Midazolam - 16
Morphine Glycopyrronium Midazolam - 15
Alfentanil Cyclizine - - 14
Oxycodone Haloperidol Hyoscine butylbromide - 14
Diamorphine Haloperidol - - 14a
Morphine Hyoscine butylbromide - - 13
Dexamethasone Ketamine - - 13
Diamorphine Cyclizine Midazolam - 13
a combinations identified as being analysed at clinically relevant doses for compatibility and stability [10–21]; note that all analysed combinations were reported
as compatible under stated conditions
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with a potential for bias. A promptness to respond to
the invitation and a willingness to participate suggests
the expert has an interest in the subject under scrutiny,
which carries a risk of self-selection bias. It has been
proposed that there is an inherent bias in Delphi studies
because experts may volunteer to take part as they hold
particular views about the subject matter, which could
influence the consensus process [28]. Nonetheless, it has
been shown that those who are willing to participate in
expert panels are representative of their unwilling col-
leagues [29]. The ‘snowballing’ technique is a conven-
tional recruitment method in Delphi research [30–32].
This technique, however, could have led to selection bias
because of its unrepresentative approach by potentially
limiting the breadth of experience and geographical
distribution of participants [33, 34].
Conclusion
Further work based on the outcomes of this study will
ensure that healthcare practitioners will have the know-
ledge and confidence that a prescribed combination can
be safely administered and that the expected therapeutic
goal will be achieved. Given the dispersion of doses
within the dataset for each drug, analysis utilising the
first and third quartiles are recommended for any future
compatibility tests. This study represents the first step
towards developing an authoritative national guide
which will inform healthcare professionals about the
administration of drugs by a CSCI.
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